Skip to content
lifestyle.successxl.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Mighty Therapeutics
Mighty Therapeutics Reports Business Highlights, Barth Syndrome Commercial Launch Update, and Pipeline Progress
October 14, 2026
Mighty Therapeutics Partners with the POLG Foundation to Develop Novel Preclinical Model for POLG Mitochondrial Disorders and Parkinson’s Disease
September 15, 2026
Mighty Therapeutics Initiates IND-Enabling Studies of MYTX-255: a Mitochondrial-Targeted Therapeutic Candidate
September 9, 2026
Mighty Therapeutics and University of Washington Team Named Milestone 2 Awardee in $101M XPRIZE Healthspan Competition
August 11, 2026
Mighty Therapeutics Secures Up to $150 Million to Progress Commercial and Clinical Development of New Class of Mitochondrial Targeted Medicines
July 14, 2026
Mighty Therapeutics Announces First Patient Dosed in Phase 4 Confirmatory Study of Elamipretide in Barth Syndrome
July 8, 2026